PF-4708671 Licensed and Manufactured by Pfizer

Catalog No.S2163

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Price Stock Quantity  
USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PF-4708671 Chemical Structure

PF-4708671 Chemical Structure
Molecular Weight: 390.41

Validation & Quality Control

2 customer reviews :

Quality Control & MSDS

Related Compound Libraries

PF-4708671 is available in the following compound libraries:

Product Information

  • Compare S6 Kinase Inhibitors
    Compare S6 Kinase Products
  • Research Area

Product Description

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.
Targets p70 S6K1 [1]
(Cell-free assay)
IC50 160 nM
In vitro PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
BHT-101MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTBwOEKwNlQh|ryPNVvqe2E{W0GQR1XS
UACC-893NVzYTJBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnGN|RKSzVyPUWuNVk5QDZizszNM160dnNCVkeHUh?=
A427MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGP6RWpKSzVyPUWuO|I2PjdizszNMofVV2FPT0WU
OCUB-MMoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mon1TWM2OD14Lk[2NVAzKM7:TR?=M2m3THNCVkeHUh?=
SW684MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFX6UpVKSzVyPUeuOVIzPjhizszNNEjIRXNUSU6JRWK=
SK-LMS-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTlwMEGzNFIh|ryPNWSydIRSW0GQR1XS
CP50-MEL-BMkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjGTWM2OD17LkOwOFE6KM7:TR?=MVrTRW5ITVJ?
NCI-H1651MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrmTWM2OD1zMD6wNlc3KM7:TR?=M3P1bXNCVkeHUh?=
ABC-1NY\LSW1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTFyLkGwN|ch|ryPM4D4dHNCVkeHUh?=
OE19MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlS3TWM2OD1zMD6xO|M{KM7:TR?=NV3UPWp1W0GQR1XS
DSH1MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPzTWM2OD1zMD64PFc6KM7:TR?=NWn5WGtyW0GQR1XS
SW13NVHsOZJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXlTWM2OD1zMT65N|E6KM7:TR?=NX;1d5BoW0GQR1XS
MDA-MB-453NUe3c2VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHFe5hKSzVyPUGyMlE3ODNizszNNEXoU5RUSU6JRWK=
647-VNFP2S4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4[4dWlEPTB;MUKuN|U5OiEQvF2=MVLTRW5ITVJ?
NCI-H2342MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGe1c|dKSzVyPUGyMlM6QTVizszNNYnOZlFyW0GQR1XS
LB2241-RCCNUfuXmVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;HfmlEPTB;MUKuOVc4QSEQvF2=MV\TRW5ITVJ?
UACC-257NHvXeHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLLVWlGUUN3ME2xN{41PDV|IN88US=>MVHTRW5ITVJ?
NCI-H661M3XpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXQXYQ{UUN3ME2xN{43PDR7IN88US=>NWPYc3AzW0GQR1XS
FADUNX7jVJRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\KcZg{UUN3ME2xN{43QTl{IN88US=>NVvqfpV5W0GQR1XS
A2780NUXlRmdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojITWM2OD1zMz64NFQyKM7:TR?=MkC0V2FPT0WU
NCI-H1793M2fv[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLETWM2OD1zND60NFg2KM7:TR?=M{npOHNCVkeHUh?=
TE-8MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmOwTWM2OD1zNT6zOFY2KM7:TR?=NYr3VIVyW0GQR1XS
HGC-27MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXWPYRKSzVyPUG2MlE3PDRizszNNYjmd4c6W0GQR1XS
MMAC-SFNVHEcm5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvvOHNKSzVyPUG3MlM4OjdizszNMYjTRW5ITVJ?
Calu-6MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPQTWM2OD1zOD6xOVE{KM7:TR?=NFTaWXJUSU6JRWK=
HUTU-80MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mkm3TWM2OD1zOD6zPVU6KM7:TR?=NFrnfG5USU6JRWK=
SASM1zQZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzlWWMyUUN3ME2xPE43PDV3IN88US=>NIK4cHJUSU6JRWK=
IST-MES1NU\VNlg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTF6Lk[1NFgh|ryPNGXwUlNUSU6JRWK=
C3AMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYmyTpR5UUN3ME2xPE44QTF7IN88US=>MWHTRW5ITVJ?
ES3MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17oOmlEPTB;MUiuPFM3PCEQvF2=MnS5V2FPT0WU
HSC-2M{DsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXi2[ZZQUUN3ME2xPU43PTRzIN88US=>NIP3WYhUSU6JRWK=
T47DMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHLUHBKSzVyPUKwMlE1QDVizszNNF\qRo1USU6JRWK=
EW-7NIHxPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFf1blBKSzVyPUKwMlg2QDhizszNNITVVGNUSU6JRWK=
LN-405MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTJyLki5OlUh|ryPMmr4V2FPT0WU
U031NFvROHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MomyTWM2OD1{MT60PFAzKM7:TR?=MXnTRW5ITVJ?
A549MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrEUo1CUUN3ME2yNU45PDlzIN88US=>NF\UUlhUSU6JRWK=
RMG-INVXsOZlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjzS3lmUUN3ME2yNk4zPjZ6IN88US=>M3jLc3NCVkeHUh?=
BT-474MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLwTWM2OD1{Mj62OVUyKM7:TR?=M1PzTHNCVkeHUh?=
NB69NWTmcnp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzqWIU6UUN3ME2yN{4yPTJizszNNGLkZ3FUSU6JRWK=
NB7M2HhRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jWWWlEPTB;MkSuNVg5KM7:TR?=MVfTRW5ITVJ?
HCC1569NVjVNXBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY[1ToZyUUN3ME2yOE43OTJ3IN88US=>MnztV2FPT0WU
MEL-JUSOMnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXmTWM2OD1{ND62PVA5KM7:TR?=NFjmUlNUSU6JRWK=
MDA-MB-175-VIIMlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DnbmlEPTB;MkWuNlUyPyEQvF2=NH7ue4ZUSU6JRWK=
HCC1419MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTJ3Lk[wNFMh|ryPMVrTRW5ITVJ?
Ca9-22NVnNOI1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH6zdlBKSzVyPUK1MlY1OzJizszNNYK2NmxXW0GQR1XS
KGNMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvBXG1KSzVyPUK1Mlc2PDdizszNNUnHeFVsW0GQR1XS
LB373-MEL-DMn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTJ4LkG5N|gh|ryPNH7HSYRUSU6JRWK=
NCI-H1755MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVj6NIJbUUN3ME2yOk45QDRzIN88US=>MYnTRW5ITVJ?
D-423MGMnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTHTWM2OD1{Nz6wO|E2KM7:TR?=MVLTRW5ITVJ?
DK-MGM{fwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjneZFPUUN3ME2yPE44QDR4IN88US=>MULTRW5ITVJ?
NCI-H1623NGDMTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{X4UWlEPTB;MkiuPFM1OiEQvF2=M4rsbHNCVkeHUh?=
KU-19-19MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfPTWM2OD1{OD65PVUh|ryPNXHVcYRDW0GQR1XS
C-33-ANX[1NohyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojVTWM2OD1{OT6yNVk5KM7:TR?=MlrTV2FPT0WU
SCC-4M{\jS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2Tm[WlEPTB;M{CuN|M2PCEQvF2=NV\r[WlvW0GQR1XS
MG-63NWfsV5pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXwb5ZKSzVyPUOwMlU6QTRizszNNIK1NlFUSU6JRWK=
LNCaP-Clone-FGCMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LZUGlEPTB;M{GuOFkzOSEQvF2=NGfrXGxUSU6JRWK=
CAPAN-1NV2ycXJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjQTWM2OD1|MT61Nlg3KM7:TR?=MWjTRW5ITVJ?
GI-ME-NNXLmbJBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LUe2lEPTB;M{GuOVM2OyEQvF2=NH7QVZFUSU6JRWK=
RERF-LC-MSNIHUNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn3yTWM2OD1|Mj62O|Q4KM7:TR?=NWW0W45IW0GQR1XS
KLEMn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnO0TWM2OD1|Mz60N|M1KM7:TR?=MlfZV2FPT0WU
KNS-81-FDNHfTW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\IRlRKSzVyPUOzMlUxODhizszNMnjyV2FPT0WU
DOKNXTu[|lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPveYFKSzVyPUO0MlY3OTJizszNNXHKdpF6W0GQR1XS
ACHNMkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfPN2xQUUN3ME2zOU4yPTh6IN88US=>NVrvcZY1W0GQR1XS
KYSE-520Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTN3LkKzOlEh|ryPMUDTRW5ITVJ?
SBC-5NG\ROJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILYPZFKSzVyPUO1MlUyOTZizszNMknOV2FPT0WU
NCI-H28NITZTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HOZWlEPTB;M{WuOlY6PSEQvF2=MXjTRW5ITVJ?
ES7MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljXTWM2OD1|Nj6yNlQ6KM7:TR?=MVfTRW5ITVJ?
A172NF\WcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTN4LkSxPFch|ryPMXPTRW5ITVJ?
UM-UC-3NXjoZ|lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTN5Lki3OFYh|ryPNVO0SIJWW0GQR1XS
LXF-289NETBVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHj0SnJKSzVyPUO4MlAxPDdizszNMYnTRW5ITVJ?
KP-4MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTN6LkS3N|kh|ryPM3ziRnNCVkeHUh?=
TE-1NYTLbXhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXhN5M1UUN3ME2zPU43PTh7IN88US=>NXT0enZ3W0GQR1XS
G-402NGjPTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHTNlNmUUN3ME20NE4xPjFizszNNWfhTpF3W0GQR1XS
786-0MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XrZmlEPTB;NECuPVA6PiEQvF2=M37vN3NCVkeHUh?=
K5MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjPdI9KSzVyPUSxMlM3QDZizszNNW\3Sm5HW0GQR1XS
SK-N-DZMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGK5dpRKSzVyPUSxMlM5OjNizszNNFjJd|JUSU6JRWK=
OVCAR-4MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjXenZKSzVyPUSxMlc2PjhizszNM3PY[3NCVkeHUh?=
T84M37DTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zOZWlEPTB;NEKuNVI3OyEQvF2=NV[yZmcxW0GQR1XS
GCIYM1e4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrWTWM2OD12Mz6wPFA{KM7:TR?=NXGxVmhuW0GQR1XS
BB49-HNCNWn3bIlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTR|LkOzOFgh|ryPM{\6RnNCVkeHUh?=
SNU-C2BMkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTsOphKSzVyPUSzMlY1OzZizszNMXrTRW5ITVJ?
TE-6Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETYd2dKSzVyPUSzMlg5QTRizszNNGm1cHhUSU6JRWK=
23132-87NFu4UYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTR2LkK5O|gh|ryPM{DiRnNCVkeHUh?=
DMS-53Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLyTWM2OD12ND6zN|g1KM7:TR?=NFTl[nRUSU6JRWK=
ONS-76MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mln3TWM2OD12ND63OlYyKM7:TR?=M2TYNnNCVkeHUh?=
DMS-273M1;aT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHGTWM2OD12ND65OFMh|ryPM4\aTXNCVkeHUh?=
COLO-824M{PBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3v[HZlUUN3ME20OU45Pzd3IN88US=>NUD5UlVUW0GQR1XS
DMS-114M4G5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fFb2lEPTB;NEWuPFkzPyEQvF2=M{\Ee3NCVkeHUh?=
YKG-1NYGzS4R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33VV2lEPTB;NE[uNFM2PSEQvF2=MnL0V2FPT0WU
RH-18M1mxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTR4LkO3N|Mh|ryPNI\3SJhUSU6JRWK=
NCI-H1355NFLYb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3wV4hKSzVyPUS2MlYyQCEQvF2=NEfBOnVUSU6JRWK=
NCI-H2170MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDTWXRKSzVyPUS3Mlc2QDRizszNMXLTRW5ITVJ?
OC-314MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1f3OmlEPTB;NEeuPFQ4QCEQvF2=M{fvbXNCVkeHUh?=
NCI-H2030M4HrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TTeWlEPTB;NEeuPFkxPiEQvF2=MWXTRW5ITVJ?
22RV1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI[0NnJKSzVyPUS3MlkxOTVizszNNWXYRmI{W0GQR1XS
G-401NYr3S5RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF24bXFKSzVyPUS4MlQ1OTVizszNNV7aU29GW0GQR1XS
YAPCMlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nkXGlEPTB;NEmuPFA4OyEQvF2=MV;TRW5ITVJ?
SW1573MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HGbGlEPTB;NUCuNlQ{PSEQvF2=NFKxO4hUSU6JRWK=
COLO-792NYXPPZJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vJXWlEPTB;NUCuOlI{PyEQvF2=MoS5V2FPT0WU
KNS-62Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PO[mlEPTB;NUCuO|UxQCEQvF2=MX\TRW5ITVJ?
NB5M1X5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHO0NlZKSzVyPUWxMlQ2ODlizszNNFTieXVUSU6JRWK=
CP66-MELNF[5[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTiTWM2OD13MT62OFA5KM7:TR?=M{iwWHNCVkeHUh?=
CaR-1M2PyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzMU3BOUUN3ME21Nk4xPjB4IN88US=>NV;XR5dLW0GQR1XS
CAL-54NV6xcHpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlu1TWM2OD13Mj6xNVAzKM7:TR?=NX7tfXBWW0GQR1XS
8305CMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorYTWM2OD13Mj6zNVUh|ryPNXjyeGVjW0GQR1XS
Calu-3MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzNTWM2OD13Mj6zO|M{KM7:TR?=NYfRUJVXW0GQR1XS
AU565NV:zbI1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLKUWtDUUN3ME21Nk42PTB7IN88US=>M4jKRnNCVkeHUh?=
CW-2NXq5NmhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTV{Lki2OVQh|ryPNWPiUIcxW0GQR1XS
BENMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIewdGpKSzVyPUWzMlc5PjJizszNMU\TRW5ITVJ?
NCI-H1975NVLxNWtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTV|Lki5OlYh|ryPNYPoTZI2W0GQR1XS
HCT-116NWrtOlZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LGR2lEPTB;NUSuNFMzPyEQvF2=MkPjV2FPT0WU
SH-4M3LFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnkVWVtUUN3ME21OE4yOzhizszNNFnj[HVUSU6JRWK=
NCI-H1693MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HW[mlEPTB;NUSuNlExOyEQvF2=NYHNdpRuW0GQR1XS
BPH-1M1yxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\VUGlEPTB;NUWuNlg6OiEQvF2=NGjLWY1USU6JRWK=
CAMA-1NFvUcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjHdFlEUUN3ME21OU45OTF4IN88US=>MkHxV2FPT0WU
A388MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIKwN5RKSzVyPUW2MlA6QDVizszNMWLTRW5ITVJ?
C2BBe1NHHZblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPEd45KSzVyPUW2MlI3OzRizszNMn\mV2FPT0WU
GAMGNEjofY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDUTWM2OD13Nj61PVU2KM7:TR?=NY\LZ|Q1W0GQR1XS
MKN28NFnncJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTV4LkiwNVMh|ryPM3nNcXNCVkeHUh?=
VA-ES-BJMlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIn1VZJKSzVyPUW2Mlg4PDVizszNNFG0OXpUSU6JRWK=
HuCCT1NXXnOmJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLKOlZKSzVyPUW3MlA1QTJizszNMn7BV2FPT0WU
BFTC-905M4LwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHYZ2Y5UUN3ME21O{4zQDl6IN88US=>NGPjUWpUSU6JRWK=
LS-123MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3[xXmlEPTB;NUeuOVY3QCEQvF2=MYDTRW5ITVJ?
LB996-RCCMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4r6bWlEPTB;NUiuNFI5PyEQvF2=M3jZOnNCVkeHUh?=
NCI-H1048M2LNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlu5TWM2OD13OD6yNVg5KM7:TR?=NGTYPYRUSU6JRWK=
COR-L105MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnoOZVKSzVyPUW4Mlc{OzdizszNNITzWlJUSU6JRWK=
OVCAR-8NYjjSYJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrXVIxKSzVyPUW5MlE4OTZizszNNHLndlJUSU6JRWK=
SK-N-FINWHvVnB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTV7LkOyNFch|ryPNVz3enBwW0GQR1XS
MES-SANWDHR2FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13hbmlEPTB;NUmuOFUxQSEQvF2=Mn\mV2FPT0WU
SCC-9NXjkc5dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XSV2lEPTB;NUmuOFc2OyEQvF2=MnzOV2FPT0WU
EFO-27M3;NfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYm3PIhpUUN3ME21PU46PDNizszNMW\TRW5ITVJ?
GT3TKBNUfye3Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTZyLk[wOFgh|ryPNIPHW5lUSU6JRWK=
HCC38NXXDdHZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHvT3RwUUN3ME22NU41Ozd7IN88US=>NEj2SVdUSU6JRWK=
MLMAMl\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDyVVlkUUN3ME22NU43OTZ|IN88US=>NUniRWJLW0GQR1XS
D-566MGMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTZ|LkWyNlQh|ryPNUjWenlqW0GQR1XS
SF295MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\BTWM2OD14Mz62OlU2KM7:TR?=NVXwVI85W0GQR1XS
ES4NFvJcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\aTmlEPTB;NkSuOFcyQSEQvF2=M4fmXnNCVkeHUh?=
CAKI-1M13G[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXtOnViUUN3ME22OE42PzJzIN88US=>M37YWnNCVkeHUh?=
OAW-28NU\nWGlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlj1TWM2OD14ND65OlQ4KM7:TR?=NYTMcFVpW0GQR1XS
NCI-H460M{K4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33teWlEPTB;NkWuNFg6PyEQvF2=MXHTRW5ITVJ?
JARNX3tW2RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInudIdKSzVyPU[1MlU2OTZizszNNXy1cG9zW0GQR1XS
SNU-449MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHTfXRKSzVyPU[1Mlc3OTZizszNM3HiXnNCVkeHUh?=
D-392MGNXe4dVQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mkm0TWM2OD14NT65OFM1KM7:TR?=Mk\uV2FPT0WU
EW-22M2fmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfSZ2lKSzVyPU[2MlM6PSEQvF2=MWHTRW5ITVJ?
GCTMlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XlcGlEPTB;NkeuNFQ1OyEQvF2=NHHpVIpUSU6JRWK=
NOS-1NHnxOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLPTWM2OD14Nz62PFY4KM7:TR?=NGfaZo5USU6JRWK=
RH-1Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\PRnZKSzVyPU[4MlU2PTlizszNMWfTRW5ITVJ?
HuH-7M1P0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHvVoxnUUN3ME22PU4yODB{IN88US=>NGHOdYtUSU6JRWK=
NUGC-3MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\qTWM2OD15MD65OlQ1KM7:TR?=Ml;sV2FPT0WU
IST-SL1NV\QbVdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTMT3p6UUN3ME23NU4zOzJ2IN88US=>M{W1cHNCVkeHUh?=
SHP-77NVTEfJU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHoTWM2OD15Mj6xNVkh|ryPMm\0V2FPT0WU
SW1116MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorRTWM2OD15Mj6xOFA4KM7:TR?=M2X5WXNCVkeHUh?=
LK-2MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LxfGlEPTB;N{KuPFYyOiEQvF2=MX7TRW5ITVJ?
U-2-OSNVL5TYJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzsR2JKSzVyPUezMlE5OjhizszNNE\GVYVUSU6JRWK=
KYSE-150MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3Hh[GlEPTB;N{OuOlEyQCEQvF2=M{L0b3NCVkeHUh?=
U251M2PyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIL2fmlKSzVyPUezMlgyPjhizszNMl3IV2FPT0WU
HT-1080MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPMTWM2OD15ND6yOVc1KM7:TR?=MUfTRW5ITVJ?
NCI-H1437M3z2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIC0eIRKSzVyPUe0MlY{OjZizszNNG\KcmZUSU6JRWK=
HPAF-IINH\mNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn3BTWM2OD15ND62OFE2KM7:TR?=NX:2XIFkW0GQR1XS
BeckerNGrXWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XERWlEPTB;N{WuNVExPSEQvF2=M1\YPXNCVkeHUh?=
PANC-10-05MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1r6WWlEPTB;N{WuNlg3PSEQvF2=M17HbXNCVkeHUh?=
TYK-nuNV:3cpVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1P6Z2lEPTB;N{WuN|ExOiEQvF2=M1fFdHNCVkeHUh?=
SKG-IIIaNIPCfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTd3LkOzOFEh|ryPMUDTRW5ITVJ?
NCI-H1993NEi2fHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTd3LkezPVch|ryPNVvuWYN{W0GQR1XS
S-117NWriUWExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTd3Lke1OUDPxE1?NXvZcXZ2W0GQR1XS
HuO9M1rRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXwTWM2OD15Nj6wNFQ5KM7:TR?=MXfTRW5ITVJ?
CAL-51MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rYb2lEPTB;N{[uNVAxPiEQvF2=MYLTRW5ITVJ?
BT-20NXT1dIM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLUTWM2OD15Nj6yNVY5KM7:TR?=MWDTRW5ITVJ?
LB831-BLCNWG5PJM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTd4LkOyNVch|ryPNV\GOY9LW0GQR1XS
LB1047-RCCM4\3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXGPY56UUN3ME23Ok44PjF7IN88US=>M1HYPHNCVkeHUh?=
ES8M{\IbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDnTWM2OD15OD6wNFc{KM7:TR?=NF7iWlJUSU6JRWK=
UMC-11MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHm2XYhKSzVyPUe4MlA5QDRizszNM2DLUnNCVkeHUh?=
NCI-H226NVfqW4J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTd6LkGzNVUh|ryPNYP1doN6W0GQR1XS
IGROV-1NXzwPW5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXaXWFTUUN3ME23PE42PTVizszNM1v2SHNCVkeHUh?=
BHYNET4enpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTd7LkW5OkDPxE1?NUn1[IMzW0GQR1XS
MKN45MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXWTWM2OD16MD6zNVc1KM7:TR?=MofvV2FPT0WU
IA-LMNFfic5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRThyLkO1NVEh|ryPMX7TRW5ITVJ?
WM-115MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjnb25KSzVyPUixMlQyOTRizszNMl;yV2FPT0WU
VMRC-RCZMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRThzLkS0NlUh|ryPMoHIV2FPT0WU
NCI-H2291MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3G0bGlEPTB;OEGuOlg1OiEQvF2=NEPQW5pUSU6JRWK=
MCF7M{LhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTUNHBYUUN3ME24N{4zQDl5IN88US=>MVjTRW5ITVJ?
639-VMmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zETWlEPTB;OESuOlEzQSEQvF2=NVvx[XpHW0GQR1XS
RT4MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\UdYpKSzVyPUi1MlI1ODNizszNNHLaVY5USU6JRWK=
NCI-H2405MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnzTWM2OD16NT6yPVk4KM7:TR?=M4iwOHNCVkeHUh?=
CAL-33MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfEUnlXUUN3ME24OU43OzF3IN88US=>MX3TRW5ITVJ?
BT-549MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLSfYE{UUN3ME24OU46Ozh{IN88US=>M1rmPXNCVkeHUh?=
HT-1197M3LUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTh6LkGwO|ch|ryPNEj2S4JUSU6JRWK=
G-361MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2Py[mlEPTB;OEiuNVQ4PCEQvF2=M4fuPXNCVkeHUh?=
LS-411NMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\OT4UxUUN3ME24PU4{Ozh6IN88US=>MnXYV2FPT0WU
HT-144MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\FTWM2OD16OT61PVkzKM7:TR?=MXjTRW5ITVJ?
DJM-1M3jKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTh7Lki4OFUh|ryPMmnVV2FPT0WU
CAL-12TMonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTtZlNvUUN3ME25NE44QDl3IN88US=>NXO5ZmE3W0GQR1XS
MKN7NH7peIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFuyZW1KSzVyPUmxMlM2PTFizszNMWHTRW5ITVJ?
HuP-T3NYrFWpFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTl4LkGwNFQh|ryPMULTRW5ITVJ?
SK-MG-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIf6RYNKSzVyPUm2MlE{PDhizszNMoXzV2FPT0WU
NCI-H2347NEG5c4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInuXGxKSzVyPUm4MlExPDJizszNMkHHV2FPT0WU
SW872NHzLVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXm4cWNGUUN3ME2xNFAvPDV4IN88US=>MYHTRW5ITVJ?
COLO-829NIfwS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmX5TWM2OD1zMECuOVU{KM7:TR?=NHfhflhUSU6JRWK=
MC-IXCMmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PLS2lEPTB;MUCwMlYyPSEQvF2=NFq4SVJUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Protein kinase activity assays For selectivity IC50 assays, purified active GST–S6K1, GST–S6K2, His–MSK1 (residues 2–802), His–RSK1 (residues 1–735) and His–RSK2 (residues 2–740) (0.5 units/mL) are assayed for 30 min at 30 °C in a 50 μL assay mixture in buffer A containing either 30 μM Crosstide (GRPRTSSFAEG, for S6K1, S6K2 and MSK1) or 30 μM Long S6 (KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, for RSK1 and RSK2), 10 mM magnesium acetate and 100 μM [γ- 32P]ATP. Reactions are terminated and the incorporation of [γ-32P]phosphate into the peptide substrate is determined by applying the reaction mixture on to P81 phosphocellulose paper and scintillation counting after washing the papers in phosphoric acid. One unit of activity is defined as that which catalysed the incorporation of 1 nmol of [32P]phosphate into the substrate. To determine the Ki for PF-4708671, full-length recombinant S6K1 is added to a final concentration of 5 nM to Omnia assay buffer containing various concentrations of compound. The reaction is run for 60 min at 30 °C in a 50 μL assay volume. The fluorescence of the peptide is monitored at an excitation wavelength of 360 nm and an emission wavelength of 485 nm. The rate of the reaction at each compound concentration is normalized to the DMSO control rate, and this normalized rate against concentration is fitted to the Morrison tight-binding equation for a competitive inhibitor to provide the true Ki. In order to assay S6K activity in HEK-293 cell lysates, cells are lysed in Tris lysis buffer. Lysate (0.5 mg) is incubated with 5 μg of S6K antibody conjugated to Protein G–Sepharose for 1 h at 4 °C on a vibrating platform. Immunoprecipitates are washed twice with lysis buffer and twice with buffer A, and kinase activity is assayed exactly as described above using the Crosstide peptide.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Chemical Information

Download PF-4708671 SDF
Molecular Weight (MW) 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 1H-Benzimidazole, 2-[[4-(5-ethyl-4-pyrimidinyl)-1-piperazinyl]methyl]-6-(trifluoromethyl)-

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related S6 Kinase Products

  • LY2584702

    LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.

  • LY2584702 Tosylate

    LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • BI-D1870

    BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • MK-2206 2HCl

    MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • CHIR-99021 (CT99021) HCl

    CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

Recently Viewed Items

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us